RAPPRapport Therapeutics Inc
RAPP
Rapport Therapeutics Inc378
Mkt Cap
$1.75BVolume
372,529.0052W High
$42.2752W Low
$7.73PE Ratio
-12.81RAPP Fundamentals
Price
$39.54Prev Close
$36.71Open
$36.4350D MA
$29.64Beta
1.46Avg. Volume
363,165.39EPS (Annual)
-$2.86P/B
3.62Rev/Employee
$0.00$702.11
Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $17,490.00 in Stock
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 500 shares of Rapport Therapeutics stock in a transaction on Friday, April 10th. The stock was sold at an average price of $34.98, for a total transaction of $17,490.00. Following the transaction, the...
MarketBeat·2d ago
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 9,165 Shares of Stock
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 9,165 shares of the company's stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $34.97, for a total value of $320,500.05. Following the transaction...
MarketBeat·2d ago
Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $357,816.00 in Stock
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 10,200 shares of the business's stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $35.08, for a total transaction of $357,816.00. Following the...
MarketBeat·2d ago
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 500 Shares
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 500 shares of the business's stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $34.98, for a total transaction of $17,490.00. Following the completion...
MarketBeat·2d ago
Rapport Therapeutics (NASDAQ:RAPP) Upgraded by Raymond James Financial to Strong-Buy Rating
Raymond James Financial upgraded shares of Rapport Therapeutics to a "strong-buy" rating in a research report on Thursday...
MarketBeat·5d ago
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated by Analysts at Raymond James Financial
Raymond James Financial initiated coverage on Rapport Therapeutics in a research report on Friday. They issued a "strong-buy" rating and a $66.00 price target on the stock...
MarketBeat·6d ago
Krishnaswamy Yeleswaram Sells 360 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 360 shares of the stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $34.90, for a total transaction of $12,564.00. Following the transaction, the insider...
MarketBeat·6d ago
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 360 Shares
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 360 shares of Rapport Therapeutics stock in a transaction that occurred on Wednesday, April 8th. The...
MarketBeat·7d ago
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the company...
MarketBeat·12d ago
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy
Rapport Therapeutics, Inc. (RAPP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·21d ago
<
1
2
...
>